This site is intended for healthcare professionals
DNA AI generated image
  • Home
  • /
  • Medical Education
  • /
  • Molecular biomarker testing for prostate cancer
  • /
  • Podcast 2: Understanding the predictive value of H...

Podcast series: Molecular biomarker testing for prostate cancer

These podcasts have been developed and funded by AstraZeneca and are intended for healthcare professionals only.
Last updated: 3rd May 2024
Published:3rd May 2024

Listen to this podcast series on metastatic castration-resistant prostate cancer (mCRPC), featuring insights from leading experts on the current molecular testing landscape and perspectives on the predictive value of HRR/BRCA mutation (BRCAm) status.

Podcast 2: Understanding the predictive value of HRR/BRCAm status in mCRPC

Dr Steven Yip (Canada), Dr Alicia Morgans (USA) and Professor Yao Zhu (China) discuss the impact of HRR/BRCAm status on prostate cancer prognosis and the resulting implications for multidisciplinary team decision-making.

Meet the experts

Dr Steven Yip.png

Dr Steven Yip

Dr Steven Yip is a medical oncologist at the Tom Baker Cancer Centre (Calgary, Alberta, Canada) and Precision Oncology Experimental Therapeutics (POET) medical lead. He is also a clinical associate professor at the University of Calgary. His research interests include PSMA PET/CT imaging and novel radiopharmaceutical drug development for advanced prostate cancer.

Disclosures: Financial support from AAA, Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Hoffmann-La Roche, Ipsen, Janssen, Merck, Novartis, OncoHelix, and Pfizer.

Dr Alicia Morgans.png

Dr Alicia Morgans

Dr Alicia Morgans is a medical oncologist specialising in prostate cancer. She is an associate professor of medicine at Harvard Medical School, Boston, Massachusetts, USA. Her research primarily focuses on novel therapeutics and the impact of prostate cancer treatment on patients’ quality of life.

Disclosures: Financial support from AAA, Astellas, AstraZeneca, Bayer, Exelixis, Janssen, Lantheus, Lilly, Loxo@Lilly, Merck, Myovant, Novartis, Pfizer, Sanofi, Sumitomo Pharma America, and Telix.

Professor Yao Zhu.png

Professor Yao Zhu

Professor Yao Zhu is a consultant urologist specialising in urologic cancers. He is a professor of oncology at Shanghai Medical College, China. His extensive research in urologic cancers, particularly prostate and bladder cancer, has led to significant contributions to the field.

Disclosures: Financial support from AstraZeneca, Bayer, and Janssen.


Developed by EPG Health for Medthority with content provided by AstraZeneca in order to help provide healthcare professionals with access to the highest quality medical and scientific information, education and associated relevant content [Z4-61966, March 2024 | Recording Z4-62398, March 2024].